Author: crjfinlayson

Loan of COP$8.5 billion (approximately CDN$3.0 million1) has an 84-month term, 10.14% coupon and revolving component with no equity dilution This loan together with the proceeds of the recent CDN$10mm equity financing put the company in a well-capitalized position to execute on its growing sales

PharmaCielo Welcomes Landmark United Nations Decision to Remove Cannabis From Narcotic Drugs List TORONTO, Canada (December 3, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (“PharmaCielo Holdings”), commends

December 20, 2020 By Dana Rohrabacher, former U.S. Congressman and PharmaCielo Advisor Here at home-base USA and throughout the world, major changes in the status of cannabis can be expected in the year ahead. After decades of senseless debate and destructive enforcement, there is now

Effective December 1, Henning von Koss has been named CEO of PharmaCielo, replacing departing CEO David Attard. Successful achievement of Q3 operational milestones: Processing and Extraction Centre (“PEC”) construction completed – one of largest current extraction footprints[1] globally; expanded product portfolio launched Plan to initiate

David Attard and Board of Directors reach mutual agreement under which David will step down as Chief Executive Officer and PharmaCielo board member, effective December 1st, 2020. Henning von Koss, currently President and a member of PharmaCielo’s Board of Directors, formerly with Bayer and 30-year

Designation brings PharmaCielo a step closer to EU-GMP compliance; supports continued expansion of medicinal-grade extract exports GACP certification is based on WHO guidelines for quality assurance and control of herbal medicines TORONTO, Canada and RIONEGRO, Colombia (November 25, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the

TORONTO, Ontario (November 23, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF) is pleased to announce the closing of its previously announced private placement of units ("Units") of the Company for gross proceeds of $10.0 million. “The closing of this offering further strengthens the Company’s balance sheet

TORONTO, Canada and MEXICO CITY, Mexico (November 19, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF) and MINO Labs S.A. de C.V. (“MINO Labs”), the founders of PharmaCielo S.A. de C.V. (“PharmaCielo Mexico”), congratulate Mexican Senate members for advancing the much-needed cannabis legislation and subsequent reform

Including Initial Shipment, PharmaCielo will deliver total 1,000 kg of product to Customer – with revenue and cash flow reflected in 2020; interim 2021 sales agreement reached for continued Q1 volume and revenue. Relationship adds U.K. and additional E.U. exposure to PharmaCielo’s current commercial relationships

TORONTO, Canada (November 16, 2020) – PharmaCielo Ltd. (“PharmaCielo” or the “Company”) (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., announced today that it will host a conference call on Monday, November